Evaluation of TATI and other markers in solid tumors.
The usefulness of tumor-associated trypsin inhibitor (TATI) in the diagnosis of various solid tumors was compared to other tumor markers occurring in serum and urine (CEA, CA19-9, CA125, CA72-4, CA50, CA15-3, CA72-4, NSE, TPA, AFP, CK-BB and ferritin). TATI was particularly well suited for the diagnosis of tumors of the pancreas, ovary, oesophagus and bladder. For tumors of these organs TATI may be considered the marker of choice. TATI was also a good marker for distinguishing between disease with or without liver metastasis in cancer of the colon and the breast.
Taccone
W
W
Analysis Laboratory, Civic Hopytal, USL 4, Avellino, Italy.
Mazzon
W
W
Belli
M
M
D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood; D015179:Colorectal Neoplasms / Q000097:blood; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000175:diagnosis*; D010051:Ovarian Neoplasms / Q000097:blood; D010190:Pancreatic Neoplasms / Q000097:blood; D011237:Predictive Value of Tests; D011471:Prostatic Neoplasms / Q000097:blood; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013274:Stomach Neoplasms / Q000097:blood; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000097:blood*; D001749:Urinary Bladder Neoplasms / Q000097:blood
D014408:Biomarkers, Tumor; D014359:Trypsin Inhibitor, Kazal Pancreatic